CANAGLIFLOZIN ANHYDROUS

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H25FO5S
Molecular Weight	444.516
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of CANAGLIFLOZIN ANHYDROUS

Structure Search

SMILES

CC1=CC=C(C=C1CC2=CC=C(S2)C3=CC=C(F)C=C3)[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O

InChI

InChIKey=XTNGUQKDFGDXSJ-ZXGKGEBGSA-N

InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C24H25FO5S
Molecular Weight	444.516
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:23:57 UTC 2023` Edited by `admin` on `Fri Dec 15 16:23:57 UTC 2023`
Record UNII	6S49DGR869
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CANAGLIFLOZIN ANHYDROUS

Common Name

English

Canagliflozin [WHO-DD]

Common Name

English

canagliflozin [INN]

Common Name

English

JNJ-28431754

Code

English

D-GLUCITOL, 1,5-ANHYDRO-1-C-(3-((5-(4-FLUOROPHENYL)-2-THIENYL)METHYL)-4-METHYLPHENYL)-

Common Name

English

(1S)-1,5-ANHYDRO-1-C-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-D- GLUCITOL

Common Name

English

(1S)-1,5-ANHYDRO-1-(3-((5-(4-FLUOROPHENYL)-2-THIENYL)METHYL)-4-METHYLPHENYL)-D-GLUCITOL

Common Name

English

TA-7284

Code

English

CANAGLIFLOZIN [MI]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000187059

Created by admin on Fri Dec 15 16:23:57 UTC 2023 , Edited by admin on Fri Dec 15 16:23:57 UTC 2023

WHO-ATC

A10BD16

Created by admin on Fri Dec 15 16:23:57 UTC 2023 , Edited by admin on Fri Dec 15 16:23:57 UTC 2023

NCI_THESAURUS

C98083

Created by admin on Fri Dec 15 16:23:57 UTC 2023 , Edited by admin on Fri Dec 15 16:23:57 UTC 2023

WHO-VATC

QA10BX11

Created by admin on Fri Dec 15 16:23:57 UTC 2023 , Edited by admin on Fri Dec 15 16:23:57 UTC 2023

WHO-ATC

A10BX11

Created by admin on Fri Dec 15 16:23:57 UTC 2023 , Edited by admin on Fri Dec 15 16:23:57 UTC 2023

WHO-ATC

A10BK02

Created by admin on Fri Dec 15 16:23:57 UTC 2023 , Edited by admin on Fri Dec 15 16:23:57 UTC 2023

Code System Code Type Description

EVMPD

SUB33463

Created by admin on Fri Dec 15 16:23:57 UTC 2023 , Edited by admin on Fri Dec 15 16:23:57 UTC 2023

PRIMARY

PUBCHEM

24812758

Created by admin on Fri Dec 15 16:23:57 UTC 2023 , Edited by admin on Fri Dec 15 16:23:57 UTC 2023

PRIMARY

NCI_THESAURUS

C91019

Created by admin on Fri Dec 15 16:23:57 UTC 2023 , Edited by admin on Fri Dec 15 16:23:57 UTC 2023

PRIMARY

NDF-RT

N0000187058

Created by admin on Fri Dec 15 16:23:57 UTC 2023 , Edited by admin on Fri Dec 15 16:23:57 UTC 2023

PRIMARY

Sodium-Glucose Transporter 2 Inhibitors [MoA]

CHEBI

73272

Created by admin on Fri Dec 15 16:23:57 UTC 2023 , Edited by admin on Fri Dec 15 16:23:57 UTC 2023

PRIMARY

CAS

842133-18-0

Created by admin on Fri Dec 15 16:23:57 UTC 2023 , Edited by admin on Fri Dec 15 16:23:57 UTC 2023

PRIMARY

FDA UNII

6S49DGR869

Created by admin on Fri Dec 15 16:23:57 UTC 2023 , Edited by admin on Fri Dec 15 16:23:57 UTC 2023

PRIMARY

SMS_ID

100000127420

Created by admin on Fri Dec 15 16:23:57 UTC 2023 , Edited by admin on Fri Dec 15 16:23:57 UTC 2023

PRIMARY

EPA CompTox

DTXSID601004469

Created by admin on Fri Dec 15 16:23:57 UTC 2023 , Edited by admin on Fri Dec 15 16:23:57 UTC 2023

PRIMARY

DRUG BANK

DB08907

Created by admin on Fri Dec 15 16:23:57 UTC 2023 , Edited by admin on Fri Dec 15 16:23:57 UTC 2023

PRIMARY

DAILYMED

6S49DGR869

Created by admin on Fri Dec 15 16:23:57 UTC 2023 , Edited by admin on Fri Dec 15 16:23:57 UTC 2023

PRIMARY

MERCK INDEX

m11716

Created by admin on Fri Dec 15 16:23:57 UTC 2023 , Edited by admin on Fri Dec 15 16:23:57 UTC 2023

PRIMARY

RXCUI

1546031

Created by admin on Fri Dec 15 16:23:57 UTC 2023 , Edited by admin on Fri Dec 15 16:23:57 UTC 2023

PRIMARY

RxNorm

INN

9225

Created by admin on Fri Dec 15 16:23:57 UTC 2023 , Edited by admin on Fri Dec 15 16:23:57 UTC 2023

PRIMARY

Related Record Type Details


					0SAC974Z85

SOLVATE->ANHYDROUS


					4AF605U6JN

MRP-2

TRANSPORTER -> SUBSTRATE


					B2L6AES9XQ

CANAGLIFLOZIN MONOHYDRATE

SOLVATE->ANHYDROUS


					6S49DGR869

CANAGLIFLOZIN ANHYDROUS

EXCRETED UNCHANGED

Qualification:

URINE

Amount:


					B2L6AES9XQ

CANAGLIFLOZIN MONOHYDRATE

SALT/SOLVATE -> PARENT


					O9NNS94T6B

URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2B4

METABOLIC ENZYME -> SUBSTRATE

Interaction Type:

MAJOR


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Comments:

Protein binding is independent of canagliflozin plasma concentrations.

Interaction Type:

BINDING

Amount:


					XAR27Q37KR

CANAGLIFLOZIN F-18

LABELED -> NON-LABELED

Amount:


					0SAC974Z85

SALT/SOLVATE -> PARENT


					3318TFY23Q

URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A9

METABOLIC ENZYME -> SUBSTRATE

Interaction Type:

MAJOR


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> SUBSTRATE


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> SUBSTRATE

Comments:

CYP3A4-mediated (oxidative) metabolism of canagliflozin is minimal (approximately 7%) in humans.

Interaction Type:

MINOR

Related Record Type Details


					5CUX9X8VFW

(1S)-1,5-ANHYDRO-1-C-(3-((5-(4-FLUOROPHENYL)-2-THIENYL)HYDROXYMETHYL)-4-METHYLPHENYL)-D-GLUCITOL

METABOLITE -> PARENT

Interaction Type:

MINOR

Qualification:

FECAL; PLASMA


					PY662S45QS

(2S,3S,4S,5R,6R)-6-((2S,3S,4R,5R,6R)-2-(3-((5-(4-FLUOROPHENYL)-2-THIENYL)METHYL)-4-METHYL-PHENYL)-3,5-DIHYDROXY-6-(HYDROXYMETHYL)TETRAHYDROPYRAN-4-YL)OXY-3,4,5-TRIHYDROXY-TETRAHYDROPYRAN-2-CARBOXYLIC ACID

METABOLITE -> PARENT

Interaction Type:

MAJOR

Qualification:

PLASMA; URINE


					64EQY425J6

(2S,3S,4S,5R,6R)-6-((2S,3R,4S,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)-2-THIENYL)METHYL)-4-METHYL-PHENYL)-4,5-DIHYDROXY-6-(HYDROXYMETHYL)TETRAHYDROPYRAN-3-YL)OXY-3,4,5-TRIHYDROXY-TETRAHYDROPYRAN-2-CARBOXYLIC ACID

METABOLITE -> PARENT

Interaction Type:

MAJOR

Qualification:

PLASMA; URINE

Related Record Type Details


					6S49DGR869

CANAGLIFLOZIN ANHYDROUS

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Biological Half-life	PHARMACOKINETIC				ORAL ADMINISTRATION SINGLE DOSE

Tmax	PHARMACOKINETIC				SINGLE DOSE ORAL ADMINISTRATION

Biological Half-life	PHARMACOKINETIC				SINGLE DOSE ORAL ADMINISTRATION

Volume of Distribution	PHARMACOKINETIC				SINGLE INTRAVENOUS ADMINISTRATION AT STEADY-STATE

ORAL BIOAVAILABILITY	PHARMACOKINETIC